CryoLife SEC Probe Compounds Firm’s Regulatory Woes; FDA Issues Notice
This article was originally published in The Gray Sheet
Executive Summary
The Securities and Exchange Commission is seeking information from CryoLife on corporate accounting from October 2001 to the present related to a company recall of tissue products, as well as stock trading activity
You may also be interested in...
Cryolife Hydrogel Technology Provides Platform For Diverse Pipeline
Atlanta-based Cryolife is preparing for human trials to support approval of its BioDisc spinal disc repair system and plans to file for an FDA investigational device exemption in the first half of 2005
Cryolife Hydrogel Technology Provides Platform For Diverse Pipeline
Atlanta-based Cryolife is preparing for human trials to support approval of its BioDisc spinal disc repair system and plans to file for an FDA investigational device exemption in the first half of 2005
CDRH Examining CryoLife Heart Valve Risks Following Tissue Recall
CDRH is reviewing potential risks associated with CryoValve heart valves in the wake of an Aug. 14 recall order for CryoLife human tissue products